About Us Contact Us

Contact Us

Send 

Search

Current Issue

2013

Vol. 12 Issue S2

On the cover: An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver

  • An update on the management of hepatitis C:guidelines for protease inhibitor-based triple therapyfrom the Latin American Association for the Study of the Liver Norberto C. Chávez-Tapia, Ezequiel Ridruejo, Angelo Alves de Mattos, Fernando Bessone, Jorge Daruich, Juan F. Sánchez-Ávila, Hugo Cheinquer, Rodrigo Zapata, Misael Uribe, Francisco Bosques-Padilla, Adrián Gadano, Alejandro Soza, Milagros Dávalos-Moscol, Cláudio Marroni Page s3-s35

    Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.

The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for the Study of the Liver and the Canadian Association for the Study of the Liver

ALEH Hepatología CASL ACEF Médica Sur
Index Copernicus PubMed

© 2016 Annals of Hepatology. All rights reserved Privacy Policy